Truist Raises its Price Target on Amgen (AMGN)

Amgen Inc. (NASDAQ:AMGN) is one of the 15 Best NASDAQ 100 Stocks to Buy Other Than SpaceX.

On July 7, 2026, Truist raised the firm’s price target on Amgen Inc. (NASDAQ:AMGN) to $340 from $327 as part of a broader Q2 earnings preview for biotech. Truist said it expects a rebound from a traditionally softer start to the year, with strength in Q2 prints for commercial franchises within its coverage. The firm also cited a robust catalyst calendar, sector optimism, and deal activity as drivers of recent momentum across biotech.

On July 8, Morgan Stanley lowered the firm’s price target on Amgen to $333 from $340 and kept an Equal Weight rating on the shares. Morgan Stanley said biotech could benefit from broader market leadership and lower interest rates, noting that historical data shows strong performance in falling rate environments because of the sector’s rate sensitivity.

Truist Raises its Price Target on Amgen (AMGN)

Last month, Mizuho analyst Salim Syed raised the firm’s price target on Amgen to $303 from $295. Syed updated the company’s model after the Q1 report.

Amgen Inc. (NASDAQ:AMGN) discovers, develops, manufactures, and delivers human therapeutics worldwide.

While we acknowledge the risk and potential of AMGN as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than AMGN and that has 10,000% upside potential, check out our report about the cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1